oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 2 )

2018 ( 18 )

2017 ( 14 )

2016 ( 23 )

Custom range...

Search Results: 1 - 10 of 9266 matches for " Steven Verjans "
All listed articles are free for downloading (OA Articles)
Page 1 /9266
Display every page Item
Editorial for proceedings papers
David Hawkridge,Kia Ng,Steven Verjans
Research in Learning Technology , 2011, DOI: 10.3402/rlt.v19i3.7816
Abstract: Here are the proceedings of the 2011 ALT Conference ‘‘Thriving in a colder and more challenging climate’’. Proceedings papers report on a piece of research, possibly in its early stages, or they can be ‘‘thoughtpieces’’ which state a point of view or summarise an area of work, perhaps giving new insights.
Editorial for proceedings papers
David Hawkridge,Steven Verjans,Gail Wilson
Research in Learning Technology , 2012, DOI: 10.3402/rlt.v20i0.19205
Abstract:
La sécurité pour des élections libres et transparentes
Pierre Verjans
Fédéralisme-Régionalisme , 2005,
Abstract:
Conclusions
Bob Kabamba,Pierre Verjans
Fédéralisme-Régionalisme , 2005,
Abstract:
Introduction générale
Jean Beaufays,Pierre Verjans
Fédéralisme-Régionalisme , 2006,
Abstract:
Introduction
Marc Jacquemain,Pierre Verjans
Fédéralisme-Régionalisme , 2003,
Abstract:
Premiers scrutins de la Troisième République Démocratique du Congo. Analyse des résultats
Bob Kabamba,Geoffroy Matagne,Pierre Verjans
Fédéralisme-Régionalisme , 2007,
Abstract:
Relación suelo-árbol y factores de sitio, en plantaciones jóvenes de teca (Tectona grandis), en la zona oeste de la cuenca del canal de Panamá
Manuel Mollinedo,Luis Ugalde,Alfredo Alvarado,Jean Mark Verjans
Agronomía Costarricense , 2005,
Abstract: Mediante la utilización de un muestreo factorial estratificado con 4 repeticiones (3x3x4) se seleccionaron 36 parcelas permanentes de medición en plantaciones de teca en la zona oeste de la cuenca del Canal de Panamá. En la estratificación se emplearon como criterios el incremento medio anual (IMA) en altura total y la pendiente del terreno. Como variables de sitio se analizaron el estado nutricional del suelo y la concentración foliar de plantaciones de teca hasta de 42 meses de edad, en las cuales se midió el incremento medio anual en altura, diámetro y volumen. Se encontró que, considerando el IMA en volumen, un 29% de las plantaciones se ubican en la clase de crecimientos bajos (2,9-4,3 m3 ha-1 a o-1), un 59% en la clase de crecimientos medios (6,3-8,3 m3 ha-1 a o-1) y un 12% (10,3-13,3 m3 ha-1 a o-1) en la clase de crecimientos altos. Las principales variables que explican las diferencias en crecimiento fueron, el porcentaje de saturación de acidez, el cual debe ser <8%, y el porcentaje de saturación de Ca >40% para lograr los mejores valores de crecimiento de los árboles; este resultado es aún más evidente cuando solo se consideran los suelos con pH<5,5. El análisis de las concentraciones foliares indica que los valores de los diferentes elementos analizados se encuentran sobre el nivel de suficiencia. A partir del procedimiento estadístico de regresión lineal por pasos y regresión lineal múltiple, se confeccionaron 2 modelos para la predicción del índice de sitio (IS) a partir de variables del suelo.
Sorafenib for advanced renal cell carcinoma in real-life practice: a literature review  [PDF]
Steven Simoens
Health (Health) , 2011, DOI: 10.4236/health.2011.32016
Abstract: Sorafenib is a new treatment indicated for patients with advanced renal cell carcinoma who have failed prior cytokine-based therapy or are considered unsuitable for such therapy. Although treatment with sorafenib under ‘ideal trial conditions’ has been extensively studied, registration and reimbursement authorities are also interested in the behavior of sorafenib in real-life practice. This study aims to conduct a literature review of the dosage and treatment duration; safety, tolerability and effectiveness; costs and cost-effectiveness of sorafenib in routine clinical care. Studies were identified by searching PubMed, Embase, Centre for Reviews and Dissemination databases, Cochrane Database of Systematic Reviews, and EconLit up to November 2010. The literature search included articles published in peer-reviewed journals, congress abstracts, and internal studies of Bayer Schering Pharma. Eight studies were included. An open-label study observed stable disease for at least eight weeks in 80% of patients. The most common drug-related adverse events were hand-foot skin reaction, rash, hypertension, and fatigue. Although treatment with sorafenib led to fewer dose reductions, it was also associated with a shorter treatment duration, less time to pro-gression and a shorter survival time as compared to sunitinib. Monthly health care costs were lower with sorafenib as compared to sunitinib. A post-marketing surveillance study showed that patients rated the tolerability and effectiveness of sorafenib as very good, good or sufficient. In conclusion, the current evidence is too limited to derive conclusions and existing studies suffer from methodological shortcomings.
Budget impact of a 10% ready-to-use intravenous immunoglobulin in the treatment of primary immunodeficiency in Belgium  [PDF]
Steven Simoens
Health (Health) , 2009, DOI: 10.4236/health.2009.13030
Abstract: The aim of this study is to compute the budget impact of adopting Kiovig, a new ready-to-use 10% liquid immunoglobulin preparation, as a treatment for primary immunodeficiency from the perspective of the Belgian health care payer. The analysis compared the “world with Kiovig” to the “world without Kiovig” and calculated how a change in the mix of immunoglobulins used to treat primary immunodeficiency would impact drug spending during 2010-2014. Data on the number of patients, immunoglobulin market shares and drug unit costs were derived from the IMS Health hospital disease database and from Belgian sources. The number of Belgian patients suffering from primary immunodefi-ciency is expected to increase from 2,378 pa-tients in 2010 to 2,447 patients in 2014. The budget impact of adopting Kiovig is likely to be modest, raising the immunoglobulin drug bud- get for this patient population by 0.4%-1.3% per year. The budgetary increase originated from the higher price of Kiovig as compared with other products, although the impact of Kiovig was limited by its anticipated slow market penetra-tion. There is a need for more and better data on the Belgian immunoglobulin market.
Page 1 /9266
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.